Transcatheter Aortic Valve Replacement (TAVR) therapy is a revolutionary new procedure for patients with severe symptomatic native aortic valve stenosis.

What is TAVR Therapy?

It’s a transcatheter procedure that enables the placement of a collapsible aortic heart valve into the body via the catheter-based RetroFlex 3 transfemoral delivery system.  This allows the Edwards SAPIEN valve to be inserted via the femoral artery in the thigh (see illustration below). The valve replaces a patient’s diseased native aortic valve without traditional open-heart surgery, while the heart continues to beat, avoiding a cardiopulmonary bypass.

Without an aortic valve replacement, 50 percent of patients will not survive more than two years after the onset of symptoms. The predicted survival of inoperable patients with severe aortic stenosis treated with standard non-surgical therapy is lower than with certain metatastic cancers.

Am I Eligible for TAVR Therapy?

Eligibility requirements for a transcatheter procedure can only be determined by a team of heart specialists. You may be a good candidate for TAVR is you have severe symptomatic native aortic valve stenosis that cannot be treated with open aortic valve replacement. Or if you have any co-existing conditions that may prevent an expected benefit from correction of the aortic stenosis.

Call the Heart Valve Center at 865-305-5223 to determine if you are a candidate.